Erythromelalgia …

Kourosh Rezania MD FAAN

General Neurology

Updated 02.02.2026
Released 12.28.2007
Expires For CME 02.02.2029

Erythromelalgia

Author: Kourosh Rezania MD FAAN

See Contributor Disclosures

Editor: Nicholas E Johnson MD MSCI FAAN

Cite this article

Erythromelalgia

In This Article

Quick Link

Introduction

Overview

The authors have summarized erythromelalgia in this article. Discoveries of sodium channel mutations help us understand various pain syndromes, including erythromelalgia. The authors further elaborate on its differential diagnosis, pathophysiology, and management options. Importantly, the role of aspirin in diagnosing and managing secondary erythromelalgia has been emphasized.

Key points

	• Erythromelalgia is characterized by episodic vasodilation associated with severe burning pain in the extremities.
	• Primary erythromelalgia can be either familial or sporadic.
	• Gain-of-function mutations of gene SCN9A (which encodes the Nav1.7 sodium channel) are present in some patients with primary erythromelalgia.
	• Secondary erythromelalgia often presents as a symptom of an underlying disease. It is often associated with myeloproliferative diseases. In these cases, it can be significantly responsive to treatment with aspirin.
	• Although many medications have been used for the treatment of erythromelalgia, the cornerstone of treatment is avoidance of triggers.

Historical note and terminology

Erythromelalgia, or “Mitchell disease,” was first described by Dr. Silas Wier Mitchell in 1878 (63). Erythromelalgia, which literally means red, painful extremities, describes an exceedingly rare, chronic condition that is characterized by the clinical triad of pronounced erythema, painful burning, and elevated skin temperature of the extremities (13; 89; 90). Clinically, erythromelalgia presents as intense redness (erythros) and severe pain (algia) in the extremities (melos). Erythermalgia, the alternative name of the condition, describes the elevated temperature (thermos) that is often noticed in the affected areas.

The genetic and molecular basis underlying primary erythromelalgia was not uncovered until the early 2000s. The inherited erythromelalgia susceptibility gene was first localized to the long arm of chromosome 2 based on a genomic analysis of one large kindred from the United States (20). Three years later, in 2004, linkage analysis identified mutations in the SCN9A gene, encoding the voltage-gated sodium channel NaV1.7, in a family with primary erythromelalgia. Studies in experimental animals have shown that the Nav1.7 sodium channel is preferentially expressed with dorsal root and sympathetic ganglion neurons (82; 72). The Nav1.7 sodium channel plays a major role in inflammatory pain (03; 66). Primary erythromelalgia is also the first known human disease that involves the Nav1.7 sodium channel.

Clinical manifestations

Presentation and course

Erythromelalgia may be either primary or secondary, depending on whether it is idiopathic or has a genetic cause (primary) or occurs in the setting of another disorder (secondary).

Primary erythromelalgia can be subdivided into familial (inherited as an autosomal dominant trait) or sporadic forms. Moreover, familial and sporadic forms of erythromelalgia can be defined as juvenile (onset of symptoms occurring before the age of 20 years; often manifesting itself before the end of the first decade of life) or adult onset. These patients experience episodic vasodilation of the extremities in association with burning pain of the feet or lower extremities (62; 89; 90; 88). Occasional sporadic cases of juvenile-onset erythromelalgia have been reported to occur due to a de novo founder mutation in the SCN9A gene of the proband (36; 37).

Secondary erythromelalgia oftentimes presents as a symptom of an underlying disease. It is commonly associated with myeloproliferative diseases, such as polycythemia vera and essential thrombocythemia but can also be seen in association with systemic conditions, including diabetes, rheumatoid arthritis, collagen vascular diseases, thrombotic thrombocytopenic purpura, hypertension, multiple sclerosis, cutaneous vasculitis, and gout, as well as with the use of certain drugs (22; 48; 79; 42). Patients with erythromelalgia in the setting of myeloproliferative disorders are often remarkably responsive to treatment with aspirin. As a corollary, any patient with erythromelalgia who responds to aspirin should be worked up for a hematological disorder. Interestingly, in the secondary form of erythromelalgia, a 2:1 predominance of females has been reported (43).

Although it is a chronic condition, symptoms tend to be more episodic than continuous and often occur following exposure to certain stimuli (05; 09). Patients describe attacks as severe burning pain with accompanying redness in the extremities in response to warm stimuli or moderate exercise (83; 67). The lower extremities are more commonly involved than the upper extremities, and involvement is usually symmetrical (13; 88). In a published noninterventional study of 13 patients with inherited erythromelalgia, it was found that erythromelalgia pain attacks are both variable in duration (with a range of 5 minutes to 780 minutes) and in intensity (with a range of 1 to 10 and an average of 5 on the Numeric Rating Scale for pain). Interestingly, there was a large amount of variation, even in patients of the same family with the same mutation of the Nav1.7 sodium channel. Moreover, there was no consistent link between the number of attacks in a day and the severity of the pain during or between attacks (60).

Clinicians should raise their index of suspicion for the disorder in patients who present with burning pain in the extremities that are red or purple in color and warm to the touch (17).

Increases in environmental temperature seem to exacerbate the condition (35). Thus, exercise, exposure to warmth (including the summer months), and long periods of standing can possibly trigger attacks in at-risk individuals (83; 67; 35). Given this finding, exposure to environments with cooler temperatures tends to mitigate symptoms in individuals with erythromelalgia (15; 35). Environmental factors, including certain foods, alcoholic beverages, and spices, have been reported to aggravate symptoms (68).

Prognosis and complications

Erythromelalgia is characterized by chronic neuropathic pain that can be difficult to treat (89; 90). Because a characteristic feature is relief obtained by immersing the extremities in ice, complications include ulceration and gangrene. In the absence of a clear etiology, treatment has been empirical and only partially effective in most cases. Early recognition and diagnosis remain cornerstones of treatment. Therefore, it is crucial for clinicians to recognize characteristic clinical signs. The condition does remit spontaneously in one third of patients (13; 89; 90). The symptoms of this debilitating condition may worsen as the patient ages (56). Furthermore, the affected areas may expand to include greater parts of the extremities, sometimes as far as the knee, as a person gets older (56). Ulceration and secondary infection of the involved skin are frequent complications, and in severe cases may progress to tissue necrosis, require amputation, cause nail growth abnormalities, and, in extreme situations, lead to septic shock (69; 86; 51). Some previous studies have suggested decreased survival compared with individuals in the general population (15; 23; 73).

Clinical vignette

Vignette 1: Primary inherited erythromelalgia. The patient was a 40-year-old male who presented with episodic erythema, mild swelling, and painful burning sensations in his feet and hands bilaterally. He reported that his symptoms began when he was about 5 years of age, although his mother stated that he had had trouble with “red, hot feet” since he was about 1 or 2 years of age. His symptoms initially only affected his feet; however, he later had similar symptoms involving his hands. Over the years, the patient had noticed that his episodes had increased in frequency and severity. At the time of presentation, he experienced multiple daily episodes of burning, throbbing pain that lasted minutes to hours.

The pain episodes were triggered by exercise or an increase in the ambient temperature. Summer months seemed to cause an increase in the frequency of painful attacks, especially if the day was hot and humid. The pain was relieved by cooling the affected extremities using a fan or submerging the areas in ice water. In fact, during the winter months, the patient often walked outside without shoes to help relieve his pain. The patient avoided most physical activities because physical exertion, such as walking uphill or running, triggered his symptoms. He also felt that his symptoms could be triggered by alcohol or caffeine consumption, spicy foods, and sometimes melon.

A review of systems was unrevealing. A review of his family history revealed that over three generations, multiple relatives had experienced similar symptoms beginning approximately at the same age. This included two of his children, his mother, his brother, his maternal aunt and uncle, and his uncle’s son and daughter. He had one maternal uncle without any symptoms.

Physical examination showed diffuse erythema over the patient’s feet and hands, extending to the ankles or wrists, respectively. Neurologic examination, including motor, reflex, and sensory examinations, was normal.

Evaluation of this patient included a brain MRI and sensory and motor nerve conduction studies of the right arm and leg, all of which were normal. Complete blood count, platelet count, blood chemistries, and antinuclear antibodies were within normal range. Testing for Fabry disease was negative. Evaluation of the SCN9A gene in this patient revealed a single amino acid substitution, which was also present in all of the tested affected family members.

Based on the patient’s clinical presentation, his family history, and the negative work-up, he was given the diagnosis of primary inherited erythromelalgia. Management included a trial of symptomatic pharmacological relief as well as pain counseling. He was advised not to submerge his extremities in cold water. He was counseled on how to maintain a cool environment, safely cool his affected extremities, and avoid triggers.

Vignette 2: Adult onset, sporadic erythromelalgia. The patient was a 41-year-old female who presented with an 8-month history of intermittent tingling and erythema as well as painful throbbing and burning sensations in her lower extremities. Her symptoms extended to approximately mid-calf, bilaterally. She noticed that her symptoms began approximately 8 months before presentation while driving home from her first day at an aerobics class she had recently joined. She had never noticed any pain or erythema on her hands or face. Her symptoms were intermittent, lasting minutes to hours, and occurred approximately two or three times per week. She occasionally had multiple episodes within 24 hours.

Her pain episodes were triggered by exercise or an increase in environmental temperature. She preferred to sleep without blankets covering her feet and often had a fan blowing on her lower extremities at night. She often wore sandals and avoided any tight-fitting pants or hosiery in an attempt to prevent the start of her symptoms.

On review of systems, she had diet-controlled hyperlipidemia. She had no history of orthostatic hypotension, gastroparesis, labile blood pressure, palpitations, or other signs of autonomic dysfunction. There were no family members with similar symptoms over the last four generations.

The patient had a normal neurologic examination. No abnormalities were seen on nerve conduction studies or electromyography. No abnormalities were noticed on laser Doppler flow examination. Subsequent quantitative sudomotor axon reflex test yielded normal findings. All of the patient’s blood work was within normal limits.

Based on the patient’s clinical presentation and negative work-up, the patient was given the diagnosis of adult-onset, sporadic erythromelalgia. Management for this patient is the same as the above patient.

Biological basis

Etiology and pathogenesis

The SCN9A gene on the 7.94 cM interval of chromosome 2q has been identified as the locus of mutations that cause the primary, hereditary form of erythromelalgia (20; 95). The SCN9A gene encodes the alpha subunit of the Nav1.7 voltage-gated sodium channel, which is predominantly expressed within both sensory and sympathetic neuronal cells (82). Primary erythromelalgia is due to missense mutations of the Nav1.7 sodium channel, which result in single amino acid substitutions in the channel alpha subunit protein and cause gain-of-function changes in channel function, most notably a hyperpolarization of activation and slowed deactivation. Because sodium channel activation results in an inward electrical current that depolarizes neurons, NaV1.7 mutations that cause erythromelalgia render dorsal root ganglion (DRG) neurons hyperexcitable. The mutant Nav1.7 channels lead to hyperexcitability in small DRG neurons by reducing the threshold for action potential firing, enabling spontaneous action potential firing, or enhancing the response to small stimuli (11; 89; 90; 88). In addition to pain-signaling DRG neurons, sympathetic peripheral fibers have also been recognized as being adversely affected by the mutations (48; 44).

Dynamic clamp studies of the L858H IEM mutation have shown that hyperexcitability of small DRG neurons, including nociceptors, is directly linked to amplification of net sodium influx (27; 84). However, these same mutations produce hypoexcitability within sympathetic ganglion neurons, which also express Nav1.7 (72), providing a basis for the abnormality of sympathetic vasomotor control seen in these patients (72). Aging h male and female mice possessing L858 Na1.7 channels experience a significant reduction in sodium conductance. This represents a functional loss, which is probably due to age-related changes in transcription and cellular compensation (92). A study has shown that stimulating hyperpolarization-activated cyclic nucleotide-gated channels leads to a reduction in the excitability and firing frequency of DRG neurons, both in those expressing the wild type and those with the L858H mutation. This effect is due to increased hyperpolarization-activated currents (85). These studies are indicative of the complex biology of sodium channels, the pathology of which can result in different phenotypes (erythromelalgia, small fiber neuropathy, and paroxysmal extreme pain syndrome), depending on the expression of other genes as well as epigenetic and environmental factors.

In addition to the variable effect on neurons, IEM mutations have also been linked to more complex clinical phenotypes. The G856R mutation of Nav1.7 was found in two siblings, both of whom have the typical symptoms of IEM, albeit to different intensities, as well as underdevelopment of their limbs (78). Although the study could show that the mutation caused a gain-of-function phenotype as is normally seen in IEM mutations, the precise link between the mutation and limb underdevelopment is not well understood. In addition to this, Huang and colleagues characterized the Nav1.7 I234T mutation from patients who not only exhibit symptoms of IEM but also have an impaired ability to sense pain (40). These patients have experienced painless fractures and corneal anesthesia. Current and dynamic clamp analyses of the channel revealed that the mutation could cause drastic membrane depolarization of a small percentage of DRG cells, resulting in a loss of excitability, which in turn results in a clinical loss-of-function phenotype. A list of Nav1.7 mutations shown to cause erythromelalgia as of 2013 is available (18).

Although paroxysmal pain disorder (previously known as familial rectal pain syndrome) has also been shown to involve mutations in the SCN9A gene, findings have concluded that the characteristic phenotypes of erythromelalgia and paroxysmal pain disorder are distinctive and easily distinguishable clinically (29). Whereas erythromelalgia most often presents as episodic vasodilation of the extremities in association with burning pain of the feet and lower extremities, paroxysmal pain disorder most often presents as recurrent bouts of burning rectal and ocular pain in association with tonic, nonepileptic seizures (29). It has been suggested that the different clinical presentations are related to different physiological effects of erythromelalgia mutations (which enhance Nav1.7 channel activation) and paroxysmal pain disorder mutations (which impair Nav1.7 inactivation).

In contrast to primary erythromelalgia, no genetic basis has been identified thus far in secondary erythromelalgia (95). In fact, secondary erythromelalgia is a distinct, acquired disorder whose development is believed to be associated with rheumatologic and autoimmune factors (76). Secondary erythromelalgia is seen in association with a myriad of systemic conditions, most particularly with myeloproliferative disorders. Its development may be related to the release of humoral components from platelets or ischemic tissues that tend to be exacerbated in the presence of certain conditions and after ingestion of various drugs, including nicardipine, verapamil, bromocriptine, nifedipine, pergolide, and pseudoephedrine (25; 50; 21; 65; 48; 93). Unlike primary erythromelalgia, which is associated with alterations of critical sodium channels, secondary erythromelalgia has been suggested to be associated with acquired vascular changes that eventually lead to local hypoxia-induced symptoms in affected areas (65). Studies suggest that the condition arises from physiological responses to stimuli driven by systemic conditions that result in maldistribution of skin microvascular blood flow, leading to inadequate nutritive perfusion at the extremities. This presumably results in hypoxic conditions and is believed to lead to the symptoms of intense burning, unremitting pain, and other symptoms that have come to distinguish the condition (65). Thus, findings point to a common pathogenetic mechanism prevalent in all cases of secondary erythromelalgia, namely, microvascular arteriovenous shunting secondary to systemic insults, some of which occur during exacerbations of systemic diseases (43; 65; 52).

Differential diagnosis

The initial diagnosis of erythromelalgia can be challenging, particularly given the many other causes of painful erythematous extremities such as:

• Complex regional pain syndrome (reflex sympathetic dystrophy)
• Thromboangiitis obliterans
• Raynaud phenomenon (primary and secondary forms)
• Burning hands and feet syndrome (idiopathic small-fiber neuropathy of elderly)
• Restricted forms of myofascial pain syndrome (fibromyalgia)
• Fabry disease (especially in males with associated clinical findings)
• Vasculitic neuropathies
• Diabetic neuropathy
• Vitamin deficiency (B12/ B1)
• Vitamin excess (pyridoxine)
• Hypothyroidism
• Collagen vascular disease (systemic lupus erythematosus, Sjögren syndrome, rheumatoid arthritis, vasculitis)
• Paraneoplastic syndrome (anti-Hu)
• Medications (amiodarone, cisplatinum, colchicine, verapamil, nifedipine, bromocriptine, ticlopidine)
• Toxins or heavy metals (acrylamide, ethylene oxide, arsenic, thallium, mercury)
• Human immunodeficiency virus neuropathy
• Small-fiber neuropathy
• Sciatica

Thus, considering an appropriate differential diagnosis in at-risk patients can help prevent misdiagnoses associated with this condition. Arriving at an accurate diagnosis requires careful attention to relevant medical history and clinical findings because no definitive laboratory criteria are available (65). Due to the difficulty with diagnosis, the average time from presentation to diagnosis is 5 years (06)

Clinicians should remember that erythromelalgia shares a number of clinical features with, and is often confused with, complex regional pain syndrome (reflex sympathetic dystrophy) because both are characterized by severe pain and vasomotor disturbances. In contrast to complex regional pain syndrome, erythromelalgia is bilateral and symmetric (63; 83; 68).

Diagnostic workup

Although early recognition and treatment of the condition represent the best probability for successfully managing erythromelalgia, diagnosis can present a challenge for clinicians (05; 68). Although the diagnosis should be guided by thorough history and physical examination, other diagnostic testing may assist in arriving at a definitive diagnosis.

Understanding of erythromelalgia suggests that the best diagnostic results can be achieved during a painful episode rather than during periods of remission (05; 68). Because the symptoms of erythromelalgia can overlap with those of small fiber neuropathy, it's advisable to include autonomic testing and assessment of intraepidermal nerve fiber density (IENFD) through a skin biopsy in the diagnostic process. In a study, only about five (approximately 10%) out of 52 patients clinically diagnosed with erythromelalgia showed abnormally low intraepidermal nerve fiber density in a skin biopsy taken from the distal leg (57). All had other causes for abnormal intraepidermal nerve fiber density: ie, two had diabetes, and in another two, numbness in the feet preceded the diagnosis of erythromelalgia. Conversely, quantitative sensory testing, Q sweat, and thermoregulatory sweat tests showed abnormalities in 50%, 46%, and 60% of the patients, respectively. This study reveals a mismatch between functional impairment and the loss of small fibers in patients with erythromelalgia. Watabe and colleagues identified a new SCN9A mutation that was associated with severe erythromelalgia and small fiber neuropathy (86). This was evidenced by an abnormal density of epidermal nerve fibers in a length-dependent manner.

Although it has been clearly demonstrated that some mutations in the gene SCN9A produce an amino acid substitution in the Nav1.7, resulting in gain-of-function changes in the channel that produce hyperexcitability of dorsal root ganglion neurons, other amino acid substitutions may be functionally tolerated by the channel, do not change its physiology, and are of unclear clinical significance. A mutation of SCN9A/Nav1.7 can only be considered pathogenic if it segregates with disease phenotype, ie, is present in multiple affected family members and not in unaffected family members, or has been shown by functional profiling to produce gain-of-function changes in the channel (91). At this time, the demonstration of a missense mutation does not have therapeutic implications, but specific blockers of Nav1.7 are being developed (77). Another study showed that SCN9A variants contribute to primary erythromelalgia in only a small subset of patients, as only four of 34 (11.7%) unrelated patients with primary erythromelalgia had gain-of-function variants in NaV1.7. (75)

Erythromelalgia secondary to myeloproliferative disease can respond dramatically to aspirin (61). In fact, patients typically report pain relief for several days after a single dose. Patients who respond to aspirin should be worked up for an associated myeloproliferative disorder (68).

In a retrospective pathological study of nine patients with clinically diagnosed erythromelalgia who underwent skin biopsies from affected areas, histological examination revealed superficial vascular ectasia accompanied by microvascular deposition of C5b-9 and variable upregulation of type I interferon expression in endothelial cells. CD56 staining demonstrated reduced autonomic innervation of the eccrine coils and arteries, consistent with patterns observed in small-fiber neuropathies (55).

Other neurologic syndromes that tend to mimic erythromelalgia include complex regional pain syndrome, chronic mountain sickness, Anderson-Fabry disease, autosomal dominant burning feet syndrome, and chronic idiopathic axonal polyneuropathy (81). Unlike erythromelalgia, complex regional pain syndrome is usually unilateral and often associated with trauma-related cytokine release, resulting in exaggerated neurogenic inflammation and pain in the affected extremities (02). Recognizing such differences is critical to arriving at an accurate diagnosis in the setting of suspected erythromelalgia. Anderson-Fabry disease is a condition that results in neuropathic pain in association with cerebrovascular, renal, and sensorineural deficits (54). In fact, sensorineural deafness can be seen in as many as 78% of patients with Anderson-Fabry disease (54). Erythromelalgia rarely affects visceral organs and tends to primarily affect the distal extremities, primarily on a superficial level. Chronic idiopathic axonal polyneuropathy presents with burning pain in the distal extremities, but unlike erythromelalgia, does not cause erythema or vasodilatory changes.

Management

Although there has been great progress in understanding erythromelalgia, many patients remain difficult to treat (89; 90). Importantly, in patients with primary erythromelalgia, genetic counseling and counseling on the chronic nature of the disease is essential (39).

All patients must be advised to avoid triggers, as well as how to cool painful extremities properly. Patients should be warned against submerging their extremities in ice or icy water due to the possibility of developing skin necrosis and ulceration. A safer option is using a fan to cool the skin. However, patients should be warned against overcooling the extremities. In a published case report, a 6-year-old girl with the L858F Nav1.7 mutation developed refractory hypothermia likely because of overcooling (80). Of note, before the event, her parents had controlled her IEM pain episodes by maintaining the ambient temperature at 15 ºC, and they continuously cooled her lower extremities with either a fan or an air conditioner. She had a complicated 4-week course in the pediatric ICU. Attempts to raise her temperature led to excruciating lower limb pain, and normalization of her temperature was only successfully accomplished after the patient was heavily sedated with ketamine.

In one report, a 19-year-old man with genetically verified erythromelalgia (L136V) who had failed multiple medical therapies underwent behavioral therapy by a psychiatrist and a clinical psychologist (41). In this therapy, he was taught how to use breathing techniques to alleviate his pain and eliminate his dependence on cold water immersion. The authors report that after treatment, although he still has burning pain in his legs, he feels no urge to immerse his limbs in cold water.

A treatment algorithm was proposed in 2023 (53). First-line therapy begins with topical treatments for at least 4 weeks to assess for efficacy.

In a 2017 study by Yang and colleagues, the effects of carbamazepine on Nav 1.7 I234T, a known erythromelalgia-causing mutation, were characterized. The study showed that the I234T mutation was in close proximity to the previously predicted carbamazepine-responsive S241T mutation in the folded channel structure (94). The study also demonstrated that the I234T mutation causes a large hyperpolarizing shift in the V1/2 of activation, making the channel easier to open, and the I234T mutation increases the firing of DRG sensory neurons across physiological temperatures. When carbamazepine was applied at a clinically relevant concentration, there was a partial correction of the hyperpolarized V1/2 of activation and a reduction in the firing of DRG sensory neurons. This study verifies the utility of the pharmacogenomic approach to treating patients.

The possibility of Nav1.7-specific sodium channel blockers, which target Nav1.7 but leave other sodium channel subsets unblocked, thereby minimizing off-target side effects, is also being explored (87; 31; 96). In a placebo-controlled, double-blind study, five patients with erythromelalgia were treated with single doses of an arylsulfonamide Nav1.7 blocker, resulting in decreased heat-induced pain in at least one of two trials in most of the patients (07). In the same study, induced pluripotent stem cells (iPSCs) from patients with erythromelalgia were successfully differentiated into sensory neurons. These iPSC-derived sensory neurons reproduce the hyperexcitability, elevated spontaneous firing frequency, and heat sensitivity seen in the clinical phenotype of erythromelalgia. Application of the selective Nav1.7 channel blocker successfully reduced the frequency of spontaneous firing, increased the action potential rheobase, and reversed the elevated heat sensitivity in the iPSC-derived sensory neurons in a manner that parallels the patients’ responses.

A published report has described a second generation of Nav1.7 selective antagonists (01). These acylsulfonamide compounds have much slower dissociation from Nav1.7 when compared to the first-generation arylsulfonamide blockers. In addition, with repeat dosing, the study demonstrated approximately 10-fold increased potency relative to first-generation compounds.

Genomic analysis, together with atomic-level structural modeling, has been used to predict the susceptibility of patients carrying an inherited erythromelalgia mutation, S241T of Nav1.7, to treatment with carbamazepine. In a double-blind crossover study of two patients with erythromelalgia from the same family carrying the S241T mutation, both patients reported a reduction in overall time in pain and duration of erythromelalgia episodes after treatment with carbamazepine. These patients also underwent fMRI scans to assess brain activity during treatment with carbamazepine and a placebo. The reduction in pain was accompanied in the fMRI scans by a shift in activity away from valuation and pain areas of the brain (areas that are activated in association with chronic pain) toward somatosensory and parietal association cortex (areas activated by acute pain) (32). A review by Li and colleagues suggested that certain pathogenic variants show differential responsiveness to pharmacologic agents (eg, p.L858F/H to mexiletine and V400M, S241T, and I234T to carbamazepine), highlighting the potential for genotype-guided, personalized treatment strategies (51). In a clinical proof-of-concept, topical high-dose mepyramine was applied to patients with severe, treatment-refractory erythromelalgia, including individuals with confirmed SCN9A mutations, leading to rapid and sustained reductions in burning pain and erythema (24). In that study, patch-clamp studies in HEK293 cells demonstrated that mepyramine blocked Nav1.7 channels harboring the I848T, L858F, and L1267V mutations, despite their distinct effects on channel gating. A potential drug in the pipeline is cyclopentane carboxylic acid 31, a potent NaV1.7 inhibitor that has demonstrated significant analgesic efficacy in a transgenic mouse model of inherited erythromelalgia, highlighting its therapeutic potential (77).

Other oral therapy options include the anticonvulsants gabapentin and pregabalin. Both medications bind to voltage-gated calcium channels. They are both frequently prescribed for neuropathic pain. In a survey, 16 patients reported symptom improvement with gabapentin (10). Studies of serotonin-reuptake inhibitors such as venlafaxine have provided promising results both in the immediate alleviation of symptoms associated with erythromelalgia and in reducing their occurrence (19; 30)

Lidocaine, either as a patch or a cream, is often tried by patients with erythromelalgia. Topical lidocaine is available in either 4% or 5% concentration, the latter of which requires a prescription. However, per a case series of 34 patients, those with more severe and longer disease duration did not respond to the lidocaine patch (16). Another topical option is amitriptyline with ketamine. Amitriptyline is a first-generation tricyclic antidepressant, whereas ketamine is an N-methyl-D-aspartate receptor antagonist. In a case series of 36 patients, 75% noted improvement with topical amitriptyline compounded with ketamine. Other topical treatment options include capsaicin cream, which desensitizes receptor TRPV1, leading to decreased release of substance P.

In terms of systemic therapy, aspirin is often tried if there are no contraindications. As discussed below, low-dose aspirin is certainly recommended for all patients with secondary erythromelalgia due to myeloproliferative disease. In a case series of 57 patients, around half found aspirin effective (16).

Systemic corticosteroids may be considered for patients identified early in their disease course. Although the exact mechanism is unclear, corticosteroids likely reduce the neurogenic inflammation contribution to erythromelalgia. In a retrospective case series, 31 patients with erythromelalgia received corticosteroids. Amongst this cohort, 15 patients had a subacute temporal profile, defined as fewer than 21 days in duration. Of these 15 patients, 13 were considered steroid-responsive. Furthermore, another subset of these patients (n=9) was identified as having a clear trigger, such as surgery, infection, or localized body trauma; of these patients, seven were steroid-responsive (70). Therefore, Ma and colleagues recommend a course of systemic corticosteroids for patients with a short disease duration and a clear trigger. The exact steroid dose to achieve efficacy is unclear, but a high-dose regimen, such as prednisone 40 mg for at least 5 days, is recommended (53).

A case study reported treatment with a combination of spinal cord stimulation and mexiletine (71). The spinal cord stimulator eradicated the pressure and throbbing pain the patient experienced, but not the burning pain. It was only with the addition of the mexiletine that the burning pain was treated. Moreover, the use of mexiletine alone was tried in this patient, but it was not as efficacious as when used in combination with the spinal cord stimulator. There have also been case reports of successful treatment of erythromelalgia with local administration of botulinum toxin A (12), with intravenous immunoglobulin (64), and topical midodrine (a selective alpha1-agonist) (14). However, it is unknown whether these treatment modalities could be widely used.

A case report has demonstrated success in a 34-year-old woman (08). In this study, she received a 3-day infusion of 0.0625% ropivacaine with 2 mcg/ml fentanyl after failing treatment with aspirin. Her pain reportedly decreased from 10/10 to 0-1/10 during the treatment. On follow-up 9 months after treatment, she reported her pain as 0-2/10. During this time, the ulcers on her lower extremities healed, and erythema resolved. She did not require opioids during this time. Although only a few case reports demonstrate success with this technique in adults, this suggests that lumbar epidural infusion might have broad efficacy in treating the symptoms of erythromelalgia in both pediatric and adult populations.

Although attempts at surgical sympathectomies have yielded conflicting results, there has been a steadily increasing number of case reports reporting apparently successful treatment of refractory erythromelalgia pain with lumbar sympathetic ganglion blockade (LSGB) (38). In two reports, LSGB, undertaken via slightly different approaches, was reported as resulting in an immediate reduction in pain scores. In the first study, two rounds of fluoroscopically-guided pulsed radiofrequency treatments were used in conjunction with 0.375% ropivacaine in a 22-year-old patient (49). This patient reported consistently lower pain scores (2 to 3, down from 6 to 8 out of 10 on the Visual Analogue Scale) for the duration of the 12 weeks she was followed in the pain clinic. In the second study, three pediatric patients (aged 5 to 17) with confirmed SCN9A mutations underwent CT fluoroscopy-guided LSGB at the L3 or L4 level with a mixture of 0.2% ropivacaine, clonidine, and triamcinolone (45). Although there was some variation in the patients’ responses, all three reported immediate and marked reduction in pain scores, with greatly reduced pain medication requirements. Also of note, these patients reported prolonged symptom relief ranging from 3 to 4 months to over 9 months. A caveat is that the number of patients reported in these studies is small, and long-term follow-up is needed. Nevertheless, taken together, these reports provide some suggestive evidence that LSGB may show promise in some patients. Additional studies will be needed to determine the best way to achieve prolonged pain relief.

Spinal cord stimulation has been previously described as a potentially efficacious pain-management modality in case reports of both adult and pediatric patients with treatment-refractory erythromelalgia (33; 71; 59; 26; 28; 46; 98). Dorsal root ganglion stimulation has also been suggested as a potential therapeutic option, trialed in one adult patient with medication-refractory erythromelalgia (34).

In secondary erythromelalgia, the key to treatment is identifying the underlying cause. Treatment of this often mitigates the symptoms and leads to remission of outbreaks. For example, phlebotomy in patients with polycythemia and normalization of platelet counts in patients with essential thrombocytopenia can initiate a commensurate decrease in secondary erythromelalgia symptoms (62). In cases where an external stimulus, such as heat, is the suspected exacerbation trigger, strict future avoidance of such stimuli should be recommended. In the event that a certain medication yields an eruption of symptoms, immediate withdrawal of the offending agent is recommended. Low doses of aspirin have been shown to reduce the incidence of both arterial and venous thrombosis, thereby improving symptoms associated with the disorder (47). Thus, prophylactic use of low-dose aspirin is recommended to all patients with secondary erythromelalgia, particularly those with polycythemia vera-induced erythromelalgia (47).

For patients with more refractory symptoms, a multidisciplinary team may be helpful, with input from neurology, pain medicine, and hematology-oncology for those with secondary erythromelalgia. Intensive pain rehabilitation programs, including physical and occupational therapy, were effective in improving the functionality of patients with severe erythromelalgia (53).

References

01: Bankar G, Goodchild SJ, Howard S, et al. Selective NaV1.7 antagonists with long residence time show improved efficacy against inflammatory and neuropathic pain. Cell Rep 2018:24(12):3133-45. PMID 30231997
02: Birklein F. Complex regional pain syndrome. J Neurol 2005;252(2):131-8. PMID 15729516
03: Black JA, Liu S, Tanaka M, Cummins TR, Waxman SG. Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain. Pain 2004;108:237-47. PMID 15030943
04: Brown GE. Erythromelalgia and other disturbances of the extremities accompanied by vasodilatation and burning. Am J Med Sci 1932;183:468-85.
05: Buttaci CJ. Erythromelalgia: a case report and literature review. Pain Med 2006;7(6):534-8. PMID 17112366
06: Caldito EG, Kaul S, Caldito NG, Piette W, Mehta S. Erythromelalgia. Part I: Pathogenesis, clinical features, evaluation, and complications. J Am Acad Dermatol 2024;90(3):453-62. PMID 37364617
07: Cao L, McDonnell A, Nitzsche A, et al. Pharmacological reversal of a pain phenotype in iPSC-derived sensory neurons and patients with inherited erythromelalgia. Sci Transl Med 2016;8(335):335ra56. PMID 27099175
08: Chinn G, Guan Z. Case report and literature review: interventional management of erythromelalgia. Transl Perioper Pain Med 2019;6(4):91-7. PMID 31592193
09: Choi JS, Dib-Hajj SD, Waxman SG. Inherited erythermalgia: limb pain from an S4 charge-neutral Na channelopathy. Neurology 2006;67(9):1563-7. PMID 16988069
10: Cohen JS. Erythromelalgia: new theories and new therapies. J Am Acad Dermatol 2000;43(5 Pt 1):841-7. PMID 11050591
11: Cummins TR, Dib-Hajj SD, Waxman SG. Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy. J Neurosci 2004;24(38):8232-6. PMID 15385606
12: da Costa AF, Meireles J, Festas MJ, Gomes A, Abreu P. Therapeutic success with local botulinum toxin in erythromelalgia. Pain Physician 2014;17(5):E658-60. PMID 25247918
13: Davis MD. Erythromelalgia. Mayo Clin Proc 2004;79(3):298. PMID 15008600
14: Davis MD, Morr CS, Warndahl RA, Sandroni P. Topically applied midodrine, 0.2%, an α1-Agonist, for the treatment of erythromelalgia. JAMA Dermatol 2015;151(9):1025-6. PMID 25946117
15: Davis MD, O’Fallon WM, Rogers RS III, Rooke TW. Natural history of erythromelalgia: presentation and outcome in 168 patients. Arch Dermatol 2000;136:330-6. PMID 10724194
16: Davis MD, Sandroni P. Lidocaine patch for pain of erythromelalgia: follow-up of 34 patients. Arch Dermatol 2005;141(10):1320-1. PMID 16230578
17: Davis MD, Sandroni P, Rooke TW, Low PA. Erythromelalgia: vasculopathy, neuropathy, or both. A prospective study of vascular and neurophysiologic studies in erythromelalgia. Arch Dermatol 2003;139:1337-43. PMID 14568838
18: Dib-Hajj SD, Yang Y, Black JA, Waxman SG. The Na(V)1.7 sodium channel: from molecule to man. Nat Rev Neurosci 2013;14(1):49-62. PMID 23232607
19: DiCaudo DJ, Kelley LA. Alleviation of erythromelalgia with venlafaxine. Arch Dermatol 2004;140(5):621-3. PMID 15148116
20: Drenth JP, Finley WH, Breedveld GJ, et al. The primary erythermalgia-susceptibility gene is located on chromosome 2q31-32. Am J Hum Genet 2001;68:1277-82. PMID 11283792
21: Drenth JP, Michiels JJ, van Joost T, Vuzevski VD. Verapamil-induced secondary erythermalgia. Br J Dermatol 1992;127(3):292-4. PMID 1390176
22: Drenth JP, Michiels JJ, van Joost T, Vuzevski VD. Secondary erythermalgia in systemic lupus erythematosus. J Rheumatol 1993;20(1):144-6. PMID 8441148
23: Drenth JP, te Morsche RH, Guillet G, Taieb A, Kirby RL, Jansen JB. SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage gated sodium channels. J Invest Dermatol 2005;124(6):1333-8. PMID 15955112
24: Ducrocq M, Penalba V, Castillo L, et al. Mepyramine targets mutant Nav1.7 channels to relieve pain and erythema in primary erythromelalgia patients. Front Med (Lausanne) 2025;12:1744968. PMID 41458489
25: Dupont E, Illum F, Olivarius Bde F. Bromocriptine and erythromelalgia-like eruptions. Neurology 1983;33(5):670. PMID 6682511
26: Eckmann M, Papanastassiou A, Awad M. A unique case for spinal cord stimulation: successful treatment of small fiber neuropathy pain using multiple spinal cord stimulators. Case Rep Med 2017;2017:6969285. PMID 28791051
27: Estacion M, Yang Y, Dib-Hajj SD, et al. A new Nav1.7 mutation in an erythromelalgia patient. Biochem Biophys Res Comm 2013;432(1):99-104. PMID 23376079
28: Fan X, Bu H, Wen Y, et al. Spinal cord stimulation in the treatment of pediatric erythromelalgia. World Neurosurg 2020;142:388-90. PMID 32652278
29: Fertleman CR, Ferrie CD, Aicardi J, et al. Paroxysmal extreme pain disorder (previously familial rectal pain syndrome). Neurology 2007;69(6):586-95. PMID 17679678
30: Firmin D, Roguedas AM, Greco M, et al. Treatment of familial erythromelalgia with venlafaxine. J Eur Acad Dermatol Venereol 2007;21(6):836-7. PMID 17567325
31: Fischer TZ, Gilmore ES, Estacion M, et al. A novel Nav1.7 mutation producing carbamazepine-responsive erythromelalgia. Ann Neurol 2009;65(6):733-41. PMID 19557861
32: Geha P, Yang Y, Estacion M, et al. Pharmacotherapy for pain in a family with inherited erythromelalgia guided by genomic analysis and functional profiling. JAMA Neurol 2016;73(6):659-67. PMID 27088781
33: Graziotti PJ, Goucke CR. Control of intractable pain in erythromelalgia by using spinal cord stimulation. J Pain Symptom Manage 1993;8(7):502-4. PMID 7963776
34: Hagedorn JM, Canzanello N, Lamer TJ. Dorsal root ganglion stimulation for erythromelalgia related foot pain: a case report and review of the literature. Pain Pract 2021;21(6):698-702. PMID 33508884
35: Han C, Lampert A, Rush AM, et al. Temperature dependence of erythromelalgia mutation L858F in sodium channel Nav1.7. Mol Pain 2007;19;3:3. PMID 17239250
36: Han C, Rush AM, Dib-Hajj SD, et al. Sporadic onset of erythermalgia: a gain in function in Nav1.7. Ann Neurol 2006;59:553-8. PMID 16392115
37: Harty TP, Dib-Hajj SD, Tyrrell L, et al. Nav1.7 mutant A863P in erythromelalgia: effects of altered activation and steady-state inactivation on excitability of nociceptive DRG neurons. J Neurosci 2006;26:12566-75. PMID 17135418
38: Hashmonai M, Cameron AE, Licht PB, Hensman C, Schick CH. Thoracic sympathectomy: a review of current indications. Surg Endosc 2016;30(4):1255-69. PMID 26123342
39: Hisama F, Dib-Hajj SD, Waxman SG. SCN9A-related inherited erythromelalgia. Located at http://www.genetests.org. 2006.
40: Huang J, Mis MA, Tanaka B, et al. Atypical changes in DRG neuron excitability and complex pain phenotype associated with a Nav1.7 mutation that massively hyperpolarizes activation. Sci Rep 2018;8(1):1811. PMID 29379075
41: Ito M, Yamaguchi S, Omine T, et al. Behavioral therapy ceased cold water immersion dependence in a patient with familial erythromelalgia caused by SCN9A mutation. JAAD Case Rep 2019;5(9):806-8. PMID 31517003
42: Jeffcoate WJ, Idris I, Game FL. Erythromelia or Mitchell's syndrome--new names for unexplained signs of inflammation in distal symmetrical neuropathy in diabetes. Diabet Med 2004;21(12):1334-8. PMID 15569137
43: Kalgaard OM, Seem E, Kvernebo K. Erythromelalgia: a clinical study of 87 cases. J Intern Med 1997;242(3):191-7. PMID 9350163
44: Kazemi B, Shooshtari SM, Nasab MR, Roghani RS, Haghighi FM. Sympathetic skin response (SSR) in erythromelalgia. Electromyogr Clin Neurophysiol 2003;43(3):165-8. PMID 12712804
45: Kundu A, Rafiq M, Warren PS, Tobias JD. Erythromelalgia in the pediatric patient: role of computed-tomography-guided lumbar sympathetic blockade. J Pain Res 2016;9:837-45. PMID 27799815
46: Lam CM, Zayed H, Sayed D. High frequency dorsal column spinal cord stimulation for management of erythromelalgia. BMJ Case Rep 2021;14(8):e244758. PMID 34353840
47: Landolfi R, Di Gennaro L, Novarese L, Patrono C. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies. Semin Thromb Hemost 2006;32(3):251-9. PMID 16673279
48: Layzer RB. Hot feet: erythromelalgia and related disorders. J Child Neurol 2001;16(3):199-202. PMID 11305688
49: Lee JY, Sim WS, Kang RA, Lee EK, Yang JY, Kim DY. Lumbar sympathetic pulsed radiofrequency treatment for primary erythromelalgia: a case report. Pediatr Dermatol 2017;34(1):e47-50. PMID 27699862
50: Levesque H, Moore N. Erythromelalgia induced by nicardipine. BMJ 1989;299(6694):323. PMID 2504422
51: Li Y, He Z, Liu Y, et al. Genetic and clinical insights into inherited erythromelalgia: a comprehensive review of cases from China and worldwide. J Invest Dermatol 2026;146(2):328-44. PMID 41190974
52: Ljubojevic S, Lipozencic J, Pustisek N. Erythromelalgia. Acta Dermatovenerol Croat 2004;12(2):99-105. PMID 15075045
53: Ma JE, Lee JU, Sartori-Valinotti JC, Rooke TW, Sandroni P, Davis MD. Erythromelalgia: a review of medical management options and our approach to management. Mayo Clin Proc 2023;98(1):136-49. PMID 36470753
54: MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001;38(11):769-75. PMID 11732485
55: Magro C, Kalomeris T, Guo L. The cutaneous pathology of erythromelalgia and its role in establishing critical clues regarding pathogenesis. Am J Dermatopathol 2025;47(3):184-90. PMID 39846717
56: Mandell F, Folkman J, Matsumoto S. Erythromelalgia. Pediatrics 1977;59:45-8. PMID 840540
57: Mantyh WG, Dyck PJB, Dyck PJ, et al. Epidermal nerve fiber quantification in patients with erythromelalgia. JAMA Dermatol 2017;153(2):162-7. PMID 27926760
58: Matarneh B, Witman P. Life-threatening hypothermia in a child with primary erythromelalgia. Pediatr Dermatol 2022;39(1):135-6. PMID 34888934
59: Matzke LL, Lamer TJ, Gazelka HM. Spinal cord stimulation for treatment of neuropathic pain associated with erythromelalgia. Reg Anesth Pain Med 2016;41(5):619-20. PMID 27512936
60: McDonnell A, Schulman B, Ali Z, et al. Inherited erythromelalgia due to mutations in SCN9A: natural history, clinical phenotype and somatosensory profile. Brain 2016;139(Pt 4):1052-65. PMID 26920677
61: Michiels JJ, Berneman Z, Schroyens W, et al. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Platelets 2006;17(8):528-44. PMID 17127481
62: Michiels JJ, te Morsche RH, Jansen JB, Drenth JP. Autosomal dominant erythermalgia associated with a novel mutation in the voltage-gated sodium channel alpha subunit Nav1.7. Arch Neurol 2005;62:1587-90. PMID 16216943
63: Mitchell SW. On a rare vaso-motor neurosis of the extremities, and on the maladies with which it may be confounded. Am J Med Sci 1878;76:17-36.
64: Moody S, Pacheco S, Butler IJ, Koenig MK. Secondary erythromelalgia successfully treated with intravenous immunoglobulin. J Child Neurol 2012;27(7):922-3. PMID 22156790
65: Mork C, Kvernebo K. Erythromelalgia--a mysterious condition. Arch Dermatol 2000;136(3):406-9. PMID 10724206
66: Nassar MA, Stirling LC, Forlani G, et al. Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain. Proc Natl Acad Sci USA 2004;101:12706-11. PMID 15314237
67: Nathan A, Rose JB, Guite JW, Hehir D, Milovcich K. Primary erythromelalgia in a child responding to intravenous lidocaine and oral mexiletine treatment. Pediatrics 2005;115(4):e504-7. PMID 15741349
68: Novella SP, Hisama FM, Dib-Hajj SD, Waxman SG. A case of inherited erythromelalgia. Nat Clin Pract Neurol 2007;3(4):229-34. PMID 17410110
69: Nwebube C, Bulancea S, Marchidann A, et. Al. Erythromelalgia: a child with V400M mutation in the SCN9A gene. Neurol Genet 2021;7(2):e570. PMID 33688580
70: Pagani-Estevez GL, Sandroni P, Davis MD, Watson JC. Erythromelalgia: identification of a corticosteroid-responsive subset. J Am Acad Dermatol 2017;76(3):506-11.e1. PMID 28413058
71: Patel N, Chen E, Cucchiaro G. The complexity of pain management in patients with erythromelalgia. A A Case Rep 2015;5(9):151-3. PMID 26528699
72: Rush AM, Dib-Hajj SD, Liu S, Cummins TR, Black JA, Waxman SG. A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. Proc Natl Acad Sci USA 2006;103(21):8245-50. PMID 16702558
73: Sandroni P, Davis MD. Combination gel of 1% amitriptyline and 0.5% ketamine to treat refractory erythromelalgia pain: a new treatment option. Arch Dermatol 2006;142(3):283-6. PMID 16549702
74: Sidiq SA, Asad U, Ren V. Prevalence of erythromelalgia in the United States: a cross-sectional study using the All of Us database. Arch Dermatol Res 2024;316(9):646. PMID 39331176
75: Skystad Kvernebo M, Grayson C, Stylianou IM, et al. Genetic variants in the SCN9A gene are detected in a minority of erythromelalgia patients. Acta Derm Venereol 2025;105:adv42022. PMID 39850993
76: Stricker LJ, Green CR. Resolution of refractory symptoms of secondary erythermalgia with intermittent epidural bupivacaine. Reg Anesth Pain Med 2001;26(5):488-90. PMID 11561273
77: Sun S, Chowdhury S, Hemeon I, et al. Discovery of novel cyclopentane carboxylic acids as potent and selective inhibitors of NaV1.7. Bioorg Med Chem Lett 2025;116:130033. PMID 39580005
78: Tanaka BS, Nguyen PT, Zhou EY, et al. Gain-of-function mutation of a voltage-gated sodium channel Nav 1.7 associated with peripheral pain and impaired limb development. J Biol Chem 2017;292(22): 9262-72. PMID 28381558
79: Tefferi A. Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clin Proc 2003;78:174-94. PMID 12583529
80: Tham SW, Li L, Effraim PR, Waxman SG. Between fire and ice: refractory hypothermia and warmth-induced pain in inherited erythromelalgia. BMJ Case Rep 2017;2017. PMID 28751508
81: Thomas PK, King RH, Feng SF, et al. Neurological manifestations in chronic mountain sickness: the burning feet-burning hands syndrome. J Neurol Neurosurg Psychiatry 2000;69(4):447-52. PMID 10990502
82: Toledo-Aral JJ, Moss BL, He ZJ, et al. Identification of PN1, a predominant voltage-dependent sodium channel expressed principally in peripheral neurons. Proc Natl Acad Sci USA 1997;94(4):1527-32. PMID 9037087
83: van Genderen PJ, Michiels JJ, Drenth JP. Hereditary erythermalgia and acquired erythromelalgia. Am J Med Genet 1993;45(4):530-2. PMID 8465864
84: Vasylyev DV, Han C, Zhao P, Dib-Hajj S, Waxman S. Dynamic-clamp analysis of wild-type Nav1.7 and erythromelalgia mutant channel L858H. J Neurophys 2014;111(7):1429-43. PMID 24401712
85: Vasylyev DV, Liu S, Waxman SG. Current stabilizes excitability in rodent DRG neurons and reverses hyperexcitability in a nociceptive neuron model of inherited neuropathic pain. J Physiol 2023;601(23):5341-66. PMID 37846879
86: Watabe D, Tominaga M, Toyama S, Takamori K, Nakano H, Amano H. A severe case of primary erythromelalgia presenting as small fiber neuropathy with a novel SCN9A mutation. J Dermatol 2023;50(7):938-41. PMID 36815391
87: Waxman SG. A channel sets the gain on pain. Nature 2006;444:831-2. PMID 17167466
88: Waxman SG. Nav1.7, its mutations, and the syndromes that they cause. Neurology 2007;69(6):505-7. PMID 17679668
89: Waxman SG, Dib-Hajj SD. Erythromelalgia: a hereditary pain syndrome enters the molecular era. Ann Neurol 2005a;57(6):785-8. PMID 15929046
90: Waxman SG, Dib-Hajj S. Erythermalgia: molecular basis for an inherited pain syndrome. Trends Mol Med 2005b;11:555-62. PMID 16278094
91: Waxman SG, Merkies IS, Gerrits MM, et al. Sodium channel genes in pain-related disorders: phenotype-genotype associations and recommendations for clinical use. Lancet Neurol 2014;13(11):1152-60. PMID 25316021
92: Wimalasena NK, Taub DG, Shim J, et al. Nav1.7 gain-of- function mutation I228M triggers age-dependent nociceptive insensitivity and C-LTMR dysregulation. Exp Neurol 2023;364:114393. PMID 37003485
93: Wong LZ, Kravvas G. Pseudoephedrine-associated erythromelalgia: a case report of a rare drug reaction. Case Rep Dermatol 2025;18(1):51-5. PMID 41550880
94: Yang Y, Adi T, Effraim PR, Chen L, Dib-Hajj SD, Waxman SG. Reverse pharmacogenomics: carbamazepine normalizes activation and attenuates thermal hyperexcitability of sensory neurons due to Nav 1.7 mutation I234T. Br J Pharmacol 2018;175(12):2261-71. PMID 28658526
95: Yang Y, Wang Y, Li S, et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet 2004;41(3):171-4. PMID 14985375
96: Yang Y, Dib-Hajj SD, Zhang J, et al. Structural modeling and mutant cycle analysis predict pharmacoresponsiveness of a Na(V)1.7 mutant channel. Nat Commun 2012;3:1186. PMID 23149731
97: Zheng ZM, Zhang JH, Hu JM, Liu SF, Zhu WP. Poxviruses isolated from epidemic erythromelalgia in China. Lancet 1988;1(8580):296. PMID 2893103
98: Zuo L, Su A, Shi Y, Li N, Chen S, Yang X. Case report: spinal cord stimulation in the treatment of pediatric erythromelalgia. Front Neurol 2023;14:1143241. PMID 37273700

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Kourosh Rezania MD FAAN

Dr. Rezania of the University of Chicago Medicine received honorarium from Amgen, Grifols, Janssen, and Takeda as a speaker and consultant.
See Profile

Editor

Nicholas E Johnson MD MSCI FAAN

Dr. Johnson of Virginia Commonwealth University received consulting fees and/or research grants from AMO Pharma, Avidity, Dyne, Novartis, Pepgen, Sanofi Genzyme, Sarepta Therapeutics, Takeda, and Vertex, consulting fees and stock options from Juvena, and honorariums from Biogen Idec and Fulcrum Therapeutics as a drug safety monitoring board member.
See Profile

Former Authors

Jamil Y Abuzetun MD
Ribhi Hazin MD
Faisal Khan MD
Tanya Z Fischer MD PhD
Emma Ciafaloni MD FAAN
Matthew Alsaloum PhD
Philip R Effraim MD PhD
Stephen G Waxman MD PhD
Shubadra Priyadarshini MD

Patient Profile

Age range of presentation: 0 month to 65+ years
Sex preponderance: In the secondary form of erythromelalgia, a 2:1 predominance of females has been reported.
Heredity: heredity typical

autosomal dominant in cases of primary erythromelalgia
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-10: Erythromelalgia: I73.8
ICD-11: Vasodilatation of extremities: EG00
OMIM: Erythermalgia, Primary: #133020

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Erythromelalgia

Associated Disorders

polycythemia vera
essential thrombocythemia
diabetes
rheumatoid arthritis
collagen vascular diseases
- thrombotic thrombocytopenic purpura
- hypertension
- multiple sclerosis
- cutaneous vasculitis
- gout

Differential Diagnosis

complex regional pain syndrome (reflex sympathetic dystrophy)
causalgia
thromboangiitis obliterans
Raynaud phenomenon
burning hands and feet syndrome
- restricted forms of myofascial pain syndrome
- fibromyalgia
- ABC syndrome (Angry, Backfiring C nociceptors)
- Fabry disease
- painful peripheral neuropathies
- diabetic neuropathy
- vitamin deficiency (B12/ B1)
- vitamin excess (pyridoxine)
- hypothyroidism
- collagen vascular disease (systemic lupus erythematosus, Sjögren syndrome, rheumatoid arthritis, vasculitis)
- paraneoplastic syndrome
- medications (amiodarone, cisplatinum, colchicine, verapamil, nifedipine, bromocriptine, ticlopidine)
- toxin or heavy metals (acrylamide, ethylene oxide, arsenic, thallium, mercury)
- human immunodeficiency virus neuropathy
- small-fiber neuropathy
- sciatica

Erythromelalgia …

Erythromelalgia

Cite this article

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Suzetrigine

Upadacitinib

Atogepant

Dextromethorphan hydrobromide and quinidine sulfate

DNA- and RNA-directed gene therapies

Headache associated with HIV and AIDS

Primary exercise headache

Amblyopia

Erythromelalgia

Cite this article

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Suzetrigine

Upadacitinib

Atogepant

Dextromethorphan hydrobromide and quinidine sulfate

DNA- and RNA-directed gene therapies

Headache associated with HIV and AIDS

Primary exercise headache

Amblyopia

This is an article preview.
Start a Free Account
to access the full version.